Search research articles
Contact Us
Filters
Showing results (91-100 of 107) with videos related to
Page
of 11
Sort By:
The Lancet. Oncology
|
April 13, 2023
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial
Sandro Pignata, Giovanni Scambia, Clorinda Schettino, et al.
The Lancet. Oncology
|
February 4, 2021
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial
Sandro Pignata, Domenica Lorusso, Florence Joly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 17, 2011
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial
Sandro Pignata, Giovanni Scambia, Gabriella Ferrandina, et al.
The Lancet. Oncology
|
March 4, 2014
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 6, 2026
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial
Christian Marth, Richard G Moore, Mariusz Bidziński, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 26, 2024
Stereotactic Ablative Radiation Therapy for Oligometastatic Ovarian Cancer Lymph Node Disease: The MITO-RT3/RAD Phase II Trial
Gabriella Macchia, Maura Campitelli, Donato Pezzulla, et al.
Gynecologic Oncology
|
April 14, 2019
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer
Sandro Pignata, Giovanni Scambia, Domenica Lorusso, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2025
Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study
Ignace Vergote, Larry J Copeland, Toon Van Gorp, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 1, 2021
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study
Gennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, et al.
Tumori
|
December 15, 2025
Letrozole for hormone receptor-positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trial
Alessio Carbone, Elena Biagioli, Vanda Salutari, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 107) with videos related to
Sort By:
Page
of 11
The Lancet. Oncology
|
April 13, 2023
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial
Sandro Pignata, Giovanni Scambia, Clorinda Schettino, et al.
The Lancet. Oncology
|
February 4, 2021
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial
Sandro Pignata, Domenica Lorusso, Florence Joly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 17, 2011
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial
Sandro Pignata, Giovanni Scambia, Gabriella Ferrandina, et al.
The Lancet. Oncology
|
March 4, 2014
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 6, 2026
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial
Christian Marth, Richard G Moore, Mariusz Bidziński, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 26, 2024
Stereotactic Ablative Radiation Therapy for Oligometastatic Ovarian Cancer Lymph Node Disease: The MITO-RT3/RAD Phase II Trial
Gabriella Macchia, Maura Campitelli, Donato Pezzulla, et al.
Gynecologic Oncology
|
April 14, 2019
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer
Sandro Pignata, Giovanni Scambia, Domenica Lorusso, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2025
Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study
Ignace Vergote, Larry J Copeland, Toon Van Gorp, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 1, 2021
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study
Gennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, et al.
Tumori
|
December 15, 2025
Letrozole for hormone receptor-positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trial
Alessio Carbone, Elena Biagioli, Vanda Salutari, et al.
Page
of 11